Vicore Pharma Holding AB (publ) VICO
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Maintain existing position; consider adding only on clear data points or a material price dip without fundamental deterioration.
Full recruitment of the ASPIRE study and cash runway into 2028 keep the risk profile unchanged while the binary topline readout in 2027 remains the primary value driver.
Sentiment has improved modestly following the positive futility analysis outcome and new analyst coverage, yet the market remains focused on the binary risk ahead of the ASPIRE topline in 2027.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 6 Nov 2026 — Report confirms study continues after positive futility analysis, driving the improved news flow.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Vicore Pharma is a Swedish biotech company developing AT2 receptor agonists (ATRAGs) for fibrotic and respiratory diseases. Its lead candidate buloxibutid (C21) is being evaluated in the global Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis (IPF). The company is pre-revenue and loss-making, but holds a strong cash position following a directed share issue.
Bull case
The US listing and completed ASPIRE recruitment strengthen the setup ahead of topline data in 2027.
Bear case
Valuation remains binary on the ASPIRE results in mid-2027 with limited news flow until then.
Why this signal
Full recruitment of the ASPIRE study and cash runway into 2028 keep the risk profile unchanged while the binary topline readout in 2027 remains the primary value driver.
Recent news
The Q3 report was released on 5 November confirming that the ASPIRE study continues as planned after a positive futility analysis. Cash runway extends into the second half of 2028.